SCHEMBL12809486

SCHEMBL12809486

Cc1ccc(-c2cc3nc(C)c(CN)c(-c4ccc(O)cc4O)n3n2)cc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 13/20 0.69
DPP8 Q6V1X1 8/20 0.62
CYP2C19 P33261 2/20 0.57
CYP3A4 P08684 1/20 0.57
CYP2C9 P11712 1/20 0.57
DPP9 Q86TI2 7/20 0.56
ALDH1A1 P00352 7/20 0.47
KDM4E B2RXH2 5/20 0.47
MAPT P10636 3/20 0.47
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
LMNA P02545 2/20 0.47
TP53 P04637 1/20 0.47
NPC1 O15118 5/20 0.45
RAB9A P51151 5/20 0.45
SMN1; SMN2 Q16637 4/20 0.45
HPGD P15428 4/20 0.44
GAA P10253 1/20 0.44
POLB P06746 1/20 0.39
NFKB1 P19838 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8256363 0.81 DPP4 (1.00) DPP4DPP8CYP2C19CYP3A4CYP2C9
SCHEMBL8258286 0.79 DPP4 (0.70) DPP4DPP8CYP2C19CYP3A4CYP2C9
SCHEMBL8256348 0.76 DPP4 (1.00) DPP4DPP8CYP2C19CYP3A4CYP2C9
SCHEMBL1407793 0.72 DPP4 (1.00) DPP4DPP8CYP2C19CYP3A4CYP2C9
SCHEMBL8258283 0.72 DPP4 (0.67) DPP4DPP8CYP2C19CYP3A4CYP2C9
SCHEMBL8256222 0.72 DPP4 (0.67) DPP4DPP8CYP2C19CYP3A4CYP2C9
SCHEMBL8256321 0.72 DPP4 (1.00) DPP4DPP8CYP2C19CYP3A4CYP2C9
SCHEMBL8256325 0.72 DPP4 (1.00) DPP4DPP8CYP2C19CYP3A4CYP2C9
SCHEMBL461032 0.71 NPC1 (0.57) DPP4DPP8CYP2C19CYP3A4CYP2C9
SCHEMBL8260568 0.67 DPP4 (1.00) DPP4DPP8CYP2C19CYP3A4CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1836206-B1 AZOLOPYRIMIDINE-BASED INHIBITORS OF DIPEPTIDYL PEPTIDASE IV AND METHODS BRISTOL MYERS SQUIBB CO (US) 2011-03-09 EP disclosed